The role of peroxisome proliferator-activated receptor gamma in prostate cancer
Despite great progress in the detection and treatment of prostate cancer, this disease remains an incredible health and economic burden. Although androgen receptor (AR) signaling plays a key role in the development and progression of prostate cancer, aberrations in other molecular pathways also cont...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2018-01-01
|
| Series: | Asian Journal of Andrology |
| Subjects: | |
| Online Access: | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=3;spage=238;epage=243;aulast=Elix |
| _version_ | 1811204377748176896 |
|---|---|
| author | Catherine Elix Sumanta K Pal Jeremy O Jones |
| author_facet | Catherine Elix Sumanta K Pal Jeremy O Jones |
| author_sort | Catherine Elix |
| collection | DOAJ |
| description | Despite great progress in the detection and treatment of prostate cancer, this disease remains an incredible health and economic burden. Although androgen receptor (AR) signaling plays a key role in the development and progression of prostate cancer, aberrations in other molecular pathways also contribute to the disease, making it essential to identify and develop drugs against novel targets, both for the prevention and treatment of prostate cancer. One promising target is the peroxisome proliferator-activated receptor gamma (PPARγ) protein. PPARγ was originally thought to act as a tumor suppressor in prostate cells because agonist ligands inhibited the growth of prostate cancer cells; however, additional studies found that PPARγ agonists inhibit cell growth independent of PPARγ. Furthermore, PPARγ expression increases with cancer grade/stage, which would suggest that it is not a tumor suppressor but instead that PPARγ activity may play a role in prostate cancer development and/or progression. Indeed, two new studies, taking vastly different, unbiased approaches, have identified PPARγ as a target in prostate cancer and suggest that PPARγ inhibition might be useful in prostate cancer prevention and treatment. These findings could lead to a new therapeutic weapon in the fight against prostate cancer. |
| first_indexed | 2024-04-12T03:12:16Z |
| format | Article |
| id | doaj.art-6eb1a67daa044b69aae84d45abbd9705 |
| institution | Directory Open Access Journal |
| issn | 1008-682X 1745-7262 |
| language | English |
| last_indexed | 2024-04-12T03:12:16Z |
| publishDate | 2018-01-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Asian Journal of Andrology |
| spelling | doaj.art-6eb1a67daa044b69aae84d45abbd97052022-12-22T03:50:18ZengWolters Kluwer Medknow PublicationsAsian Journal of Andrology1008-682X1745-72622018-01-0120323824310.4103/aja.aja_15_17The role of peroxisome proliferator-activated receptor gamma in prostate cancerCatherine ElixSumanta K PalJeremy O JonesDespite great progress in the detection and treatment of prostate cancer, this disease remains an incredible health and economic burden. Although androgen receptor (AR) signaling plays a key role in the development and progression of prostate cancer, aberrations in other molecular pathways also contribute to the disease, making it essential to identify and develop drugs against novel targets, both for the prevention and treatment of prostate cancer. One promising target is the peroxisome proliferator-activated receptor gamma (PPARγ) protein. PPARγ was originally thought to act as a tumor suppressor in prostate cells because agonist ligands inhibited the growth of prostate cancer cells; however, additional studies found that PPARγ agonists inhibit cell growth independent of PPARγ. Furthermore, PPARγ expression increases with cancer grade/stage, which would suggest that it is not a tumor suppressor but instead that PPARγ activity may play a role in prostate cancer development and/or progression. Indeed, two new studies, taking vastly different, unbiased approaches, have identified PPARγ as a target in prostate cancer and suggest that PPARγ inhibition might be useful in prostate cancer prevention and treatment. These findings could lead to a new therapeutic weapon in the fight against prostate cancer.http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=3;spage=238;epage=243;aulast=Elixandrogen receptor; PPAR gamma; prevention; prostate cancer; warfarin |
| spellingShingle | Catherine Elix Sumanta K Pal Jeremy O Jones The role of peroxisome proliferator-activated receptor gamma in prostate cancer Asian Journal of Andrology androgen receptor; PPAR gamma; prevention; prostate cancer; warfarin |
| title | The role of peroxisome proliferator-activated receptor gamma in prostate cancer |
| title_full | The role of peroxisome proliferator-activated receptor gamma in prostate cancer |
| title_fullStr | The role of peroxisome proliferator-activated receptor gamma in prostate cancer |
| title_full_unstemmed | The role of peroxisome proliferator-activated receptor gamma in prostate cancer |
| title_short | The role of peroxisome proliferator-activated receptor gamma in prostate cancer |
| title_sort | role of peroxisome proliferator activated receptor gamma in prostate cancer |
| topic | androgen receptor; PPAR gamma; prevention; prostate cancer; warfarin |
| url | http://www.ajandrology.com/article.asp?issn=1008-682X;year=2018;volume=20;issue=3;spage=238;epage=243;aulast=Elix |
| work_keys_str_mv | AT catherineelix theroleofperoxisomeproliferatoractivatedreceptorgammainprostatecancer AT sumantakpal theroleofperoxisomeproliferatoractivatedreceptorgammainprostatecancer AT jeremyojones theroleofperoxisomeproliferatoractivatedreceptorgammainprostatecancer AT catherineelix roleofperoxisomeproliferatoractivatedreceptorgammainprostatecancer AT sumantakpal roleofperoxisomeproliferatoractivatedreceptorgammainprostatecancer AT jeremyojones roleofperoxisomeproliferatoractivatedreceptorgammainprostatecancer |